GlucoLight, Patent for Sentris-100™ Blood Glucose Monitoring Technology

September 26, 2007 - GlucoLight Corporation, a development-stage company focused on blood glucose monitoring in the acute care environment, announced that it has been awarded U.S. Patent No. 7,254,429 for the technology that is the core of the company’s first product, the Sentris-100™ glucose monitor... Sentris-100 is currently in clinical testing and the Company recently completed its first hypoglycemic “clamping study” that measured blood glucose fluctuations in volunteer subjects with Type 1 diabetes..... GlucoLight's Press Release -

Biodel , U.S. Patent Covering Lead Product Candidates VIAject(TM) and VIAtab(TM)

Sept 27, 2007 - Biodel Inc. (Nasdaq: BIOD) announced the receipt of a notice of issuance from the United States Patent and Trademark Office (USPTO) for the Company's patent encompassing VIAject(TM) and VIAtab(TM), Biodel's two product candidates in clinical trials...
...VIAject(TM) is a rapid-acting injectable human insulin intended for meal- time use by patients with Type 1 or Type 2 diabetes...VIAtab(TM) is a sublingual tablet formulation of insulin... Biodel's Press Release -

Innocoll , phase 2 clinical trials for the treatment and prevention of infected diabetic foot ulcers

September 26, 2007 – Innocoll, Inc., a privately-held specialty pharmaceutical company, announced the following status and progress updates regarding its clinical development programs and specialty pharmaceutical operations:
.....CollaRx® GENTAMICIN TOPICAL to commence a series of phase 2 clinical trials for the treatment and prevention of infected diabetic foot ulcers... Innocoll 's Press Release -

Theratechnologies' Glucagon-like Peptide-1 (GLP-1) portfolio of analogues for the treatment of diabetes

September 26, 2007 - Theratechnologies (TSX:TH) announced the signing of a license agreement under which OctoPlus N.V. (Euronext: OCTO) has acquired exclusive worldwide rights to develop and commercialize Theratechnologies' Glucagon-like Peptide-1 (GLP-1) portfolio of analogues for the treatment of diabetes and other potential indications...
Theratechnologies' Press Release -
OctoPlus' Press Release -

Nastech Pharmaceutical, Phase 2 Clinical Trial for Insulin Nasal Spray to Treat Diabetes

Sept. 26, 2007 - Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) announced the start of a Phase 2 clinical trial evaluating the Company's rapid-acting Insulin Nasal Spray in approximately 20 patients with type 2 diabetes... Nastech Pharmaceutical's Press Release -

Incyte , Proof-of-Concept Results For INCB13739, 11beta-HSD1 Inhibitor in Type 2 diabetes

Sept. 25, 2007--At the 2007 UBS Global Life Sciences Conference, Incyte Corporation (Nasdaq:INCY) will announce positive proof-of-concept clinical results from the following trials:
... an ongoing 28-day Phase IIa placebo-controlled two-step hyperinsulinemic clamp trial in Type 2 diabetes for INCB13739, its lead orally available 11beta-HSD1 inhibitor... Incyte's Press Release - UBS Global Life Sciences Conference [PDF Agenda] -

PuriCore's Vashe, Wound Therapy System

September 24, 2007-PuriCore (LSE: PURI), the life sciences company focused on the control of infectious pathogens with its novel, safe antimicrobial technology, announced new clinical results from successful case studies showing the safety and efficacy of its FDA-cleared Vashe Wound Therapy Solution in a variety of clinical applications... These and other positive clinical results were presented at the New Cardiovascular Horizons and Management of the Diabetic Foot & Wound Healing Conference in New Orleans, LA, September 5-8, and will be presented this week at Georgetown University Hospital's Diabetic Limb Salvage Conference in Washington, DC... PuriCore's Press Release [PDF] -

CytRx, iroxanadine for the treatment of diabetic foot ulcers Clinical Trial Updates

Sept. 24, 2007--CytRx Corporation (NASDAQ:CYTR) a biopharmaceutical company engaged in the development and commercialization of human therapeutics, today provided updates to its designs for its clinical trials with its orally-administered molecular chaperone-based drug candidates arimoclomol for the treatment of patients with ALS and in stroke recovery, and iroxanadine for the treatment of diabetic foot ulcers... CytRx's Press Release -

Biodel has expanded its two ongoing pivotal Phase III clinical trials of VIAject(TM) into Europe

Sept 21, 2007- Biodel Inc. (Nasdaq: BIOD) today announced that the Company has expanded its two ongoing pivotal Phase III clinical trials of VIAject(TM) into Europe. Clinical sites have been initiated in Germany and patient treatment has begun...The two studies, one enrolling 400 Type 1 diabetic patients and the other enrolling 400 Type 2 diabetic patients.. Biodel's Press Release -

Pfizer and EFSD, New Research Program Focused on Cardiovascular Risk in Patients with Diabetes

September 21, 2007 -Pfizer and the European Foundation for the Study of Diabetes (EFSD) announced today, at the European Association for the Study of Diabetes (EASD) Annual Meeting, the development of a new awards program which will provide research grants to support European research around understanding and reducing cardiovascular risk in patients with diabetes... Pfizer's Press Release -

Cytomedix, FDA Clearance For AutoloGel

Sep. 20, 2007 – Cytomedix, Inc. (AMEX: GTF) today announced that the FDA has granted marketing clearance for the AutoloGelTM System. The indications for use are as follows:
Under the supervision of a healthcare professional, the PRP gel produced by the AutoloGel™ System is suitable for exuding wounds, such as leg ulcers, pressure ulcers, diabetic ulcers and for the management of mechanically or surgically-debrided wounds... Cytomedix's Press Release -

CoMentis, Diabetic Macular Edema Clinical Trial with JDRF

September 20, 2007 – The Juvenile Diabetes Research Foundation, the world's largest charitable funder of type 1 diabetes research, announced a partnership with CoMentis, Inc. to support the biotechnology company’s human clinical trial of ATG3, a topical eye drop therapy for diabetic macular edema... CoMentis' Press Release -

Generex , paper entitled Ii-Key/MHC class II epitope hybrid technology to detect T cell response to insulin and GAD in type 1 diabetes

Sept. 18, 2007 - Generex Biotechnology Corporation (NasdaqCM:GNBT), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced that it will be making a podium presentation at the 43rd Annual Meeting of the European Society Association for the Study of Diabetes (EASD) in Amsterdam, The Netherlands, September 17 - 21, 2007.... The technology used by Professor Pozzilli's group, developed at Antigen Express, facilitates detection of autoimmune responses that underlie Type-1 Diabetes Mellitus... Generex 's press Release -

Biodel , VIAject(TM) Phase II Meal Study Data

Sept 18, 2007- Biodel Inc. (Nasdaq: BIOD) announced additional clinical data from its VIAject(TM) program at the 43rd Scientific Sessions of the European Association for the Study of Diabetes (EASD).
VIAject(TM) Phase II meal study data was disclosed in an oral presentation at EASD entitled, "Pharmacokinetics and pharmacodynamics of insulin VIAject(TM), lispro and regular human insulin when injected subcutaneously immediately before a meal in patients with Type 1 diabetes."... Biodel's Press release -

Oculus Innovative Sciences, Phase II Study for Microcyn(R) Technology in Mildly Infected Diabetic Foot Ulcers

Sep 17, 2007 -Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) announced that it held an investigator meeting yesterday at the Interscience Conference on Antimicrobial Agents and Chemotherapy in Chicago...Sixteen medical centers and clinics across the United States are participating in the current Phase II trial, which is a 60-patient, randomized and open-label Phase II study to evaluate the preliminary safety and efficacy of topical Microcyn(R) Technology for the treatment of mildly infected diabetic foot infections... Oculus Innovative Sciences' Press Release -

Metabasis Therapeutics, Promising Preclinical Results with Its Novel Glucagon Antagonist for the Treatment of Type 2 Diabetes

Sept. 17, 2007--Metabasis Therapeutics, Inc. (Nasdaq: MBRX) announced that a poster entitled "A Novel Glucagon Antagonist Inhibits Glucagon-Stimulated Glucose Production in Human Hepatocytes and Lowers Blood Glucose in Animal Models of Type 2 Diabetes" was presented during the 43rd Annual Meeting of the European Association for the Study of Diabetes (Amsterdam, The Netherlands). The poster provides data from several preclinical studies that show a class of small molecule glucagon antagonists discovered by Metabasis has demonstrated promising glucose lowering activity in various animal models of type 2 diabetes... Metabasis Therapeutics' Press Release -

MicroIslet and Progenitor Cell Therapy , Agreement for the Manufacturing of MicroIslet-P

Sept. 17, 2007 - MicroIslet, Inc. (OTCBB:MIIS), a development-stage biotechnology company with patented and proprietary technologies focused on transplantation therapy for people with insulin-dependent diabetes, and Progenitor Cell Therapy, LLC (PCT), a leading cell therapy services company, announced today that they have signed an agreement for the manufacturing of MicroIslet's premier product, MicroIslet-P(tm), an Encapsulated Islet Cell Product for the Treatment of Type 1 Diabetes... Press release -

Isis, Collaboration With Ortho-McNeil, for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases

Sept 13, 2007 - Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced a broad collaboration with Ortho-McNeil, Inc., a Johnson & Johnson company, to discover, develop and commercialize antisense drugs to treat metabolic diseases, including Type 2 diabetes. As part of the collaboration, Isis will grant to Ortho-McNeil worldwide development and commercialization rights to two of its diabetes development candidates, ISIS 325568 and ISIS 377131, which selectively inhibit the production of glucagon receptor (GCGR) and glucocorticoid receptor (GCCR), respectively...Isis Pharmaceuticals' Press Release -

Pharmacopeia, Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)

Sep 12, 2007 - Pharmacopeia (NASDAQ: PCOP), an innovator in the discovery and development of novel small molecule therapeutics, today announced that based on initial results from the Company’s Phase 1 multiple ascending dose (MAD) study of its lead internal product candidate, PS433540 (DARA), no safety or tolerability issues were observed with any of the doses under evaluation...PS433540 is a dual-acting angiotensin (AII) and endothelin (ET1) receptor antagonist that is being developed as a potential treatment for hypertension and diabetic nephropathy... Pharmacopeia's Press Release -

Diabetes Detection, second-generation pager prototype is preparing to go to clinical trials.

September 11, 2007 - Hathaway Corporation (HWYI), a company that focuses on acquiring, developing, and managing disruptive technologies in the telecommunications, medical devices, and software fields that change the way companies grow and service their business globally, has announced that its subsidiary, Diabetes Detection Inc. (DDI), has completed its second-generation pager prototype, and is preparing to go to clinical trials. DDI is a next-generation medical device company addressing the Diabetes epidemic worldwide through the diagnosis and monitoring of Neuropathy -- an early sign of Diabetes... read the press release -

XOMA, Phase 1 European Trial in Diabetes for XOMA 052,

Sep 12, 2007 - XOMA Ltd. (Nasdaq:XOMA) today announced the start of a second Phase 1 clinical study of XOMA 052, a potent monoclonal antibody targeting Interleukin-1 beta (IL-1 beta), in patients with Type 2 diabetes. IL-1 plays a role in multiple inflammatory diseases and has been implicated in the pathogenesis of Type 2 diabetes through the destruction of the pancreatic islet cells that produce insulin... XOMA's Press Release [PDF] -

Living Cell Technologies, Ethics Approval for Diabetes Clinical Trial

12 September 2007 - Living Cell Technologies Ltd (ASX:LCT, OTC:LVCLY) is pleased to announce that it has obtained all the regulatory and ethics approvals required by the NZ Minister of Health before proceeding with its type 1 diabetes phase I/IIa clinical trial in New Zealand... Living Cell Technologies' Press release [PDF] -

Phosphagenics, Phase 2 TPM/Insulin clinical trial

12 September 2007 - Phosphagenics Limited (ASX: POH, AIM: PSG, OTCQX: PPGNY) announced that it has received approval to commence a Phase 2 clinical trial of its proprietary transdermal insulin, TPM/Insulin... Phosphagenics' Press Release -

Quigley Pharma’s Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy

September 11, 2007 - The Quigley Corporation (NASDAQ QGLY) issued an update on a Phase IIb Clinical Study of QR-333 on Diabetic Peripheral Neuropathy by its wholly owned subsidiary, Quigley Pharma.
The update on the study noted that over 100 subjects have been enrolled, 52 subjects have completed treatment and over 225 subjects have been screened for the Phase IIB study designed to evaluate the safety and efficacy of the topical formulation on subjects with diabetic peripheral neuropathy... Quigley Pharma's Press Release -

XTL Biopharmaceuticals , Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain

10 September 2007 - XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB; LSE: XTL; TASE: XTL) announced the initiation of a Phase IIb clinical trial of Bicifadine - a serotonin and norepinephrine reuptake inhibitor (SNRI) - for the treatment of diabetic neuropathic pain... XTL Biopharmaceuticals' Press Release -

Sernova, Sertoli Cells Successfully Engineered to Secrete Insulin, Effective in Preclinical Models of Diabetes

September 10, 2007 - Sernova Corp. (TSX-V: SVA) would like to congratulate Dr. Jannette Dufour and Ms. Katie Halley who have reversed diabetes in an animal model by genetically engineering Sertoli cells to secrete insulin... Sernova's Press Release -

OSI Pharmaceuticals, Positive Results from a Metformin Drug Interaction Study with Its DP-IV Inhibitor, PSN9301

Sept. 6, 2007--OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced that (OSI) Prosidion, its UK subsidiary focused on the discovery and development of diabetes and obesity therapeutics, reported positive results from a metformin drug interaction study in healthy volunteers with its dipeptidyl peptidase-IV (DP-IV) inhibitor, PSN9301... read here the OSI Pharmaceuticals' Press Release -

Alba Therapeutics, IND for Beta Cell Preservation in Type 1 Diabetes Using AT-1001

Sept. 5, 2007 - Alba Therapeutics Corporation :
its Investigational New Drug Application for oral AT-1001 for the preservation of endogenous insulin production capacity in new-onset type 1 diabetes (T1D) patients, has cleared the 30 day deliberation period by the U.S. Food and Drug Administration (FDA). The Company plans to initiate an exploratory diabetes study in 2008 ... Read (PDF)Alba Therapeutics' Press Release. -

PhytoMedical , Preliminary Research Results For New Class of Diabetes Compounds

September 4, 2007 - PhytoMedical Technologies, Inc. (OTCBB: PYTO) announced preliminary results from recent low-dosage animal studies of the Company’s compounds for type-2 diabetes. The compounds being tested are synthetic versions of the isolated active metabolite derived from cinnamon and potentially represent an entirely new class of compounds for the treatment of type-2 diabetes... Read PhytoMedical Technologies' Press Release -

Isis Pharmaceuticals Phase 1 Study of ISIS 325568 Targeting Glucagon Receptor to Treat Type 2 Diabetes

Sept 04, 2007 - Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) has initiated a Phase 1 study of ISIS 325568, an antisense drug designed to improve blood glucose control in patients with type 2 diabetes by inhibiting production of the glucagon receptor (GCGR). Isis Pharmaceuticals' Press Release. -

Kane Biotech, diabetic foot ulcers's application

Sept. 4, 2007 - Kane Biotech's (TSX VENTURE:KNE) CSO prepares a report on the recent research related to the potential application of the Company's DispersinB^TM technology together with bacteriophage for biofilm-based chronic wound treatment (diabetic foot ulcers included) . Kane Biotech's Press Release from Marketwire.

GlucoLight, first hypoglycemic clamping study of its continuous, non-invasive glucose monitor, Sentris-100

August 22, 2007 - GlucoLight Corporation, company focused on blood glucose monitoring in the acute care environment, announced the successful conclusion of the company’s first hypoglycemic “clamping” study to evaluate its continuous, non-invasive glucose monitor, Sentris-100™. - GlucoLight's Press Room (PDF) -